NLGN3

NLGN3 is an X-linked postsynaptic cell-adhesion molecule that organizes synapse assembly and, through proteolytic shedding of its ectodomain, acts as a paracrine signaling factor in both physiological and pathological contexts (PMID:12669065, PMID:37699715). At the synapse it engages two distinct transsynaptic pathways—a canonical interaction with neurexins and a noncanonical interaction with PTPδ—that differentially regulate higher-order brain functions including social motivation, spatial memory, and contextual fear (PMID:38475840). Its surface expression and synaptic currents are controlled by CDK5, which associates with NLGN3 in vivo and phosphorylates serine 725 to regulate NLGN3 association with the Rho-GEF Kalirin-7 (PMID:37699715). NLGN3 is cleaved from the cell surface by ADAM10, and the shed ectodomain functions as a soluble ligand that activates Gαi1/3–PI3K–Akt–mTOR signaling: in neurons this confers neuroprotection against ischemia-reperfusion injury (PMID:37880221), and in cardiac endothelial cells it drives proliferation, tube formation, and angiogenesis after myocardial infarction (PMID:41398092). In glioma the same shed NLGN3 axis is co-opted as a growth driver, activating PI3K-AKT, ERK, and LYN signaling, with LYN upregulating ADAM10 to form an autocrine cleavage feedback loop (PMID:34485271, PMID:29777576); NLGN3 expression is transcriptionally amplified by Wnt/β-catenin signaling and by a USP7–KPNB1–YBX1 axis in which YBX1 binds the NLGN3 promoter, promoting cancer stem cell properties and tumor proliferation (PMID:38254206, PMID:37443071). Autism-associated missense variants impair ER processing and maturation of NLGN3, reduce plasma membrane localization, and decrease extracellular cleavage, triggering an unfolded protein response (PMID:12669065, PMID:31184401).

1. 2003 Medium

   Established NLGN3 as a synaptic cell-adhesion molecule and linked it to disease, defining defective synaptogenesis as a candidate mechanism for autism-spectrum disorders.

   Evidence Genetic sequencing of affected sibling pairs with postsynaptic localization assignment

   PMID:12669065

   Open questions at the time

   • No biochemical reconstitution of the synaptogenic mechanism
   • Causal mutation effect not functionally tested in this study
2. 2018 Medium

   Resolved how NLGN3 promotes tumor growth non-cell-autonomously, showing that ADAM10-dependent shedding of neuronal NLGN3 is required to stimulate glioblastoma proliferation.

   Evidence ADAM10 inhibition of neuron-conditioned medium with patient-derived and cell-line GBM growth assays

   PMID:29777576

   Open questions at the time

   • Downstream receptor on GBM cells not identified here
   • Single lab, pharmacological inhibition only
3. 2019 Medium

   Showed that autism-associated missense variants act by disrupting NLGN3 maturation rather than synaptic binding per se, retaining immature protein in the ER and triggering a UPR.

   Evidence Overexpression in HEK293/HeLa with flow cytometry, immunofluorescence, and western blot, including benign control variants

   PMID:31184401

   Open questions at the time

   • Heterologous overexpression, not neuronal context
   • Functional synaptic consequences not measured
4. 2019 Medium

   Extended NLGN3's pro-proliferative role to neuroblastoma and identified PI3K/AKT-FOXO as the effector pathway through rescue by pathway inhibition.

   Evidence Proliferation, colony, cell-cycle, BrdU and xenograft assays with PI3K/AKT inhibition

   PMID:31150649

   Open questions at the time

   • Receptor mediating NLGN3 signaling not defined
   • Single lab
5. 2021 Medium

   Defined an autocrine feedback circuit in glioma whereby NLGN3 signaling through LYN upregulates ADAM10 to amplify its own cleavage and downstream PI3K-AKT/ERK signaling.

   Evidence Knockdown/overexpression in two glioma lines with ADAM10 inhibition and proliferation/migration/invasion assays

   PMID:34485271

   Open questions at the time

   • Direct NLGN3 receptor not identified
   • Feedback loop quantification limited to two cell lines
6. 2023 High

   Identified CDK5 as a kinase that phosphorylates NLGN3 at S725 to control its surface expression, Kalirin-7 association, and synaptic currents, providing a post-translational regulatory mechanism for synaptic function.

   Evidence Knock-in mouse Co-IP, in vitro kinase assay, S725 mutagenesis, surface expression assay, and patch-clamp electrophysiology

   PMID:37699715

   Open questions at the time

   • Upstream signals activating CDK5-NLGN3 phosphorylation unknown
   • Link to disease variants not tested
7. 2023 Medium

   Demonstrated a physiological neuroprotective role for shed NLGN3, showing it activates Gαi1/3-Akt-mTOR signaling in neurons and requires ADAM10 cleavage for protection against ischemic injury.

   Evidence OGD/R in SH-SY5Y and primary neurons with Gαi1/3 knockdown/KO, ADAM10 inhibition, viral NLGN3 manipulation, and MCAO mouse model

   PMID:37880221

   Open questions at the time

   • NLGN3 receptor coupling to Gαi1/3 not structurally defined
   • Single lab
8. 2023 Medium

   Connected NLGN3 to glioma stemness, showing Wnt/β-catenin transcriptionally upregulates NLGN3 and that secreted NLGN3 induces cancer stem cell properties, with DAB2IP as a suppressor.

   Evidence Conditioned medium and recombinant NLGN3 treatment, CSC sphere/marker assays, Wnt inhibition, DAB2IP manipulation

   PMID:37443071

   Open questions at the time

   • Mechanism of DAB2IP targeting of NLGN3 unresolved
   • Single lab
9. 2024 High

   Mapped a transcriptional control axis for NLGN3 in glioblastoma in which USP7 stabilizes KPNB1, which imports YBX1 to bind and activate the NLGN3 promoter.

   Evidence Co-IP/MS, ChIP, nuclear fractionation, ubiquitination assays, knockdown functional assays, and intracranial tumor model

   PMID:38254206

   Open questions at the time

   • Whether this axis operates in non-tumor neurons unknown
   • Upstream regulation of USP7 not addressed
10. 2024 Medium

    Genetically dissected NLGN3's two transsynaptic pathways, showing the noncanonical PTPδ interaction governs social reward and remote spatial memory while the neurexin interaction governs contextual fear, separating distinct behavioral outputs.

    Evidence Pathway-selective Nlgn3 knock-in mice with social conditioned place preference, Barnes maze, and fear conditioning

    PMID:38475840

    Open questions at the time

    • Synaptic/circuit-level basis of behavioral divergence not resolved
    • Single lab
11. 2024 Medium

    Extended the shed-NLGN3/Gαi1/3 paracrine mechanism to the cardiovascular system, showing NLGN3 binds Gαi1/3 in endothelial cells to drive angiogenesis and cardiac repair after infarction.

    Evidence Co-IP, Gαi1/3 KO MI model, endothelial-specific NLGN3 knockdown, ADAM10 inhibition, tube formation/proliferation assays

    PMID:41398092

    Open questions at the time

    • Receptor coupling NLGN3 to Gαi1/3 not identified
    • Single lab
12. 2025 Low

    Proposed a mechanotransduction mechanism in which shed NLGN3 binds CSPG4 to promote its ADAM10 shedding and activate PIEZO1, maintaining OPC stemness and glioma growth.

    Evidence Binding assays, ADAM10 inhibition, PIEZO1 activity and OPC differentiation/glioma assays (preprint)

    PMID:bio_10.1101_2025.07.12.664340

    Open questions at the time

    • Preprint, not peer-reviewed; abstract-level detail insufficient to assess rigor
    • Direct CSPG4 binding interface undefined
13. 2026 Low

    Used a cross-species ortholog model to test variant functional consequences, showing human NLGN3 rescues fly Nlg3-null phenotypes and that disease variants exert variant-specific gain- or loss-of-function effects on synapse morphology, sleep, and vesicle dynamics.

    Evidence Transgenic Drosophila rescue/overexpression with confocal synapse imaging, sleep assays, and vesicle dynamics imaging (preprint)

    PMID:41929011

    Open questions at the time

    • Preprint, Drosophila system; relevance to mammalian synapses unconfirmed
    • Mechanistic basis of gain- vs loss-of-function not resolved

• The cell-surface receptor(s) that couple shed NLGN3 to Gαi1/3-PI3K-Akt-mTOR signaling across neurons, glioma, and endothelium remain unidentified, leaving the entry point of the paracrine signaling axis undefined.
• No receptor mediating Gαi1/3 activation identified
• Whether one receptor serves all cell types is unknown